National Working Group Meeting on ALK diagnostics in lung cancer

W.A. Cooper, S.B. Fox, S.A. O'Toole, A.L. Morey, G. Frances, N. Pavlakis, K.J. O'Byrne, A.J. Dettrick, T. Leong, V. Rathi, D.V. Spagnolo, Christine Hemmings, M.K. Singh, D.F.C. Moffat, M. Tsao -, K.D. Wilner, R.S. Buller, S. Pitman Lowenthal, S.E. Arifeen, J. BinkoM.N. Alam

    Research output: Contribution to journalArticlepeer-review

    14 Citations (Scopus)


    The global landscape of molecular testing is rapidly changing, with the recent publication of the International Association for the Study of Lung Cancer (IASLC)/College of American Pathologists (CAP) guidelines and the ALK Atlas. The IASLC/CAP guidelines recommend that tumors from patients with non-small cell lung cancer (NSCLC) be tested for ALK rearrangements in addition to epidermal growth factor receptor (EGFR) mutations. The spur for this recommendation is the availability of novel therapies that target these rearrangements. This article is based on coverage of a Pfizer-sponsored National Working Group Meeting on ALK Diagnostics in Lung Cancer, held around the 15th World Lung Cancer Conference, in Sydney on October 31, 2013. It is based on the presentations given by the authors at the meeting and the discussion that ensued. The content for this article was discussed and agreed on by the authors. © 2014 Wiley Publishing Asia Pty Ltd.
    Original languageEnglish
    Pages (from-to)11-17
    JournalAsia-Pacific Journal of Clinical Oncology
    Issue numberSUPPL.2
    Publication statusPublished - 2014


    Dive into the research topics of 'National Working Group Meeting on ALK diagnostics in lung cancer'. Together they form a unique fingerprint.

    Cite this